Public call for experts with experience in the co-administration of treatment for drug-resistant TB and hepatitis C
A recent systematic review, commissioned by the World Health Organization (WHO), demonstrated that the prevalence of chronic hepatitis C virus (HCV) infection is high among patients with TB. Published evidence on the safety and effectiveness of co-administering treatment for rifampicin-resistant TB and HCV co-infection is extremely scarce and insufficient as a basis to develop global policy recommendations on this intervention.
To respond to the need for guidance in this area in the absence of published data, WHO's Global TB Program, is initiating a process to collect ‘Expert Evidence’ with a deadline 31 May 2023.
Full details about the public call are available here.
